This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nu Skin Trims View on Anticipated Declines in Mainland China
by Zacks Equity Research
Nu Skin's (NUS) Q2 and 2019 results are likely to be hurt by weak performance in China, triggered by government's product review initiatives.
Nu Skin Gains from Product Launches, Currency Rates Hurt
by Zacks Equity Research
Nu Skin's (NUS) customer base rises steadily, courtesy of effective marketing strategies and launches. However, adverse impacts of currency rates are concerns.
Why Is Nu Skin (NUS) Down 25.1% Since Last Earnings Report?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Up 6% in a Month: Can It Maintain Momentum?
by Zacks Equity Research
Nu Skin (NUS) focuses on capturing greater market share through sales leaders. However, the company is battling currency headwinds.
Nu Skin (NUS) Beats on Q1 Earnings & Revenues, Q2 View Soft
by Zacks Equity Research
The performance can be attributed to Nu Skin's (NUS) technology and business expansion initiatives as well as customer acquisition and retention program.
Nu Skin Enterprises (NUS) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What You Must Note Ahead of Nu Skin (NUS) Q1 Earnings
by Zacks Equity Research
Nu Skin's (NUS) is likely to benefit from effective marketing programs, gains from social media and a solid sales leaders' network. These factors are set to drive customer count in Q1.
Nu Skin Boasts Customer Growth, Faces Weak Gross Margin
by Zacks Equity Research
Nu Skin (NUS) gains from an expanding customer base and prudent product launches. However, persistent decline in gross margin is a concern.
Estee Lauder's Buyouts & Robust Online Business Bode Well
by Zacks Equity Research
Estee Lauder's (EL) solid focus on buyouts, travel retail network, effective launches and strong online sales are impressive.
NUS vs. IPAR: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUS vs. IPAR: Which Stock Is the Better Value Option?
Can Value Investors Consider Nu Skin (NUS) Stock Now?
by Nabaparna Bhattacharya
Nu Skin (NUS) stock may be a good choice for value-oriented investors right now from multiple angles.
Zacks.com featured highlights include: Materion, Boston Beer , Nu Skin, Darden and Comfort Systems
by Zacks Equity Research
Zacks.com featured highlights include: Materion, Boston Beer , Nu Skin, Darden and Comfort Systems
Coty Picks Up Steam, Stock Rallies 59% Since Q2 Results
by Zacks Equity Research
Coty's (COTY) Luxury unit continues to deliver a strong show. Also, acquisitions and e-commerce efforts bode well amid hurdles like soft Consumer Beauty segment.
Will Strong Demand Fuel United Natural's (UNFI) Q2 Earnings
by Zacks Equity Research
United Natural's (UNFI) Q2 results to gain from robust demand conditions and buyouts. However, rising fright costs and unfavorable consumer mix are concerns.
What Bargain Hunting? Bet on 5 Stocks With Rising P/E
by Sanghamitra Saha
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
British American (BTI) 2018 Earnings: Pricing a Key Catalyst
by Zacks Equity Research
British American's (BTI) preliminary 2018 results to gain from robust pricing as well as growth in low-risk tobacco products.
Factors Setting the Tone for FEMSA (FMX) in Q4 Earnings
by Zacks Equity Research
FEMSA's (FMX) fourth-quarter 2018 results might be hurt by higher operating expenses. However, its strategic actions to boost growth remain encouraging.
Estee Lauder Hits 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Estee Lauder (EL) gains from a solid focus on buyouts, travel retail network, effective launches and strong online sales.
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
by Zacks Equity Research
Zacks.com featured highlights include: Ralph Lauren, Nu Skin, Tilly's, Centene and STAAR
Here's Why Estee Lauder (EL) Looks Lucrative Post Q2 Earnings
by Zacks Equity Research
Estee Lauder (EL) has been gaining on buyouts, strong travel retail network and sturdy online sales. These factors drove Q2 results, which was followed by a raised outlook.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Avon (AVP) Stock Down on Q4 Earnings and Revenues Miss
by Zacks Equity Research
Avon (AVP) posts dismal fourth-quarter 2018 results. Further, it witnesses a decline in both its Active and Ending Representatives.
NUS vs. EL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NUS vs. EL: Which Stock Is the Better Value Option?
Nu Skin (NUS) Q4 Earnings Surpass Estimates, Decrease Y/Y
by Zacks Equity Research
Nu Skin (NUS) delivers better-than-expected fourth-quarter 2018 results, wherein the top line improves year over year on solid performances across most regional segments.
Nu Skin Enterprises (NUS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 1.94% and 1.48%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?